Focal Segmental Glomerulosclerosis Clinical Trial
NCT03493685 | Phase 3 | Interventional
Have you or a loved one been diagnosed with focal segmental glomerulosclerosis? You may be eligible to participate in a focal segmental glomerulosclerosis clinical trial.
- Currently Recruiting
- Male & Female Participants
- 8-75 years old
*This study is looking to recruit 300 participants
To determine the long-term nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with primary focal segmental glomerulosclerosis (FSGS).